Home/Investors/RA Capital Management

RA Capital Management

Biotech Investor · 11 portfolio companies

Portfolio

11

Combined Value

$11.7B

Focus Areas

20

Top Stage

Phase 2

Investment Focus

Pulmonary Hypertension Rare Diseases Cardiopulmonary Oncology Rare Genetic Diseases Skeletal Disorders Cardiovascular Hypertension Nephrology Women's Health Breast Cancer Solid Tumors Fibrotic Diseases Metabolic Diseases Autoimmune Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
Liquidia Corporation	Approved	$3.2B	Pulmonary Hypertension, Rare Diseases
Tyra Biosciences	Phase 2	$2.0B	Oncology, Rare Genetic Diseases
Mineralys Therapeutics	Phase 2	$2.0B	Cardiovascular, Hypertension
Olema Pharmaceuticals	Phase 3	$1.2B	Oncology, Women's Health
Bicara Therapeutics	Phase 1/2	$1.2B	Oncology, Solid Tumors
CytomX Therapeutics	Phase 1	$757.3M	Oncology
Tectonic Therapeutic	Phase 1	$561.0M	Cardiovascular, Fibrotic Diseases
Vor Biopharma	Phase 3	$499.9M	Autoimmune Diseases, Immunology
Kala Pharmaceuticals	Phase 2	$215.8M	Ophthalmology, Rare Diseases
PMV Pharmaceuticals	Phase 1/2	$78.4M	Oncology, Precision Medicine
Advanced Cellular Dynamics	Phase 1/2	—	Oncology, Autoimmune Diseases

Frequent Co-Investors

Public shareholders1 shared Public market investors1 shared Longitude Capital1 shared Atlas Venture1 shared Fidelity1 shared Other institutional and public shareholders1 shared Medicxi1 shared Foresite Capital1 shared